These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Amitriptyline-perphenazine and doxepin in depressed outpatients: a controlled double-blind study.
    Author: Rickels K, Csanalosi I, Werblowsky J, Weise CC, Weinstock R, Brown AS, Winokur A, Von Poelnitz M.
    Journal: J Clin Psychiatry; 1982 Oct; 43(10):419-22. PubMed ID: 6749826.
    Abstract:
    Amitriptyline-perphenazine (100/8-150/12 mg/day) and doxepin (100-150 mg/day) were compared for clinical efficacy and safety in a sample of 130 nonpsychotic depressed outpatients. Maximum study duration was 4 weeks; 19 amitriptyline-perphenazine and 29 doxepin patients completed less than or equal to 3 weeks of treatment and 45 amitriptyline-perphenazine and 37 doxepin patients completed 4 weeks of treatment. Patients in both groups showed significant improvement in depression, but amitriptyline-perphenazine produced greater improvement than doxepin on several measures of depressive symptomatology. The incidence of anticholinergic and sedative side effects was higher in the amitriptyline-perphenazine treated group.
    [Abstract] [Full Text] [Related] [New Search]